Articles
| Open Access |
https://doi.org/10.37547/ijmsphr/Volume07Issue05-09
Modern Strategies For Correction Of Metabolic Disorders In Cardiorenal Syndrome
Abstract
The article examines metabolic disorders such as insulin resistance, hyperglycemia, and dyslipidemia in patients with chronic heart failure (CHF) and chronic kidney disease (CKD). These disorders play a key role in the progression of both diseases. The article analyzes modern therapeutic approaches, including the use of SGLT2 inhibitors and mineralocorticoid receptor antagonists, as well as the importance of personalized therapy.
Keywords
Cardiorenal syndrome, metabolic disorders, insulin resistance
References
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with CKD and type 2 diabetes: FIDELIO-DKD trial. Kidney Int. 2019;96(2):469-481. doi:10.1016/j.kint.2019.11.028.
Bakris G.L. et al. (2021). Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 383, pp. 2219-2229.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
Bhatt D.L. et al. (2021). Sotagliflozin Reduces Heart Failure Events in Patients with Diabetes and CKD Regardless of Albuminuria Status. Journal of the American College of Cardiology, 78(1), pp. 101-110.
Cooper M.E. et al. (2021). The Interplay between Diabetes, Heart Failure, and Chronic Kidney Disease: Mechanisms and Therapeutic Implications. Diabetologia, 64(2), pp. 271-281.
Filippatos G., Anker S.D., Böhm M. et al. (2022). Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease Diabetes. Journal of the American College of Cardiology, 79(12), pp. 1508-1518.
Heerspink H.J.L. et al. (2021). Rationale and Design of the EMPA-KIDNEY Study. Clinical Journal of the American Society of Nephrology, 16(1), pp. 124-136.
Jardine M.J. et al. (2021). The Role of Finerenone in Cardiorenal Protection. Lancet Diabetes & Endocrinology, 9(7), pp. 649-659.
Kemp C.D., Conte J.V. (2021). The Pathophysiology of Heart Failure. Cardiovascular Pathology, 30(2), pp. 79-89.
McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. (2021). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 385(16), pp. 1451-1461.
Perkovic V. et al. (2021). Cardiorenal Outcomes with Finerenone in Patients with CKD and T2D. New England Journal of Medicine, 385, pp. 2252-2263.
Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Greenlaw N, et al. Safety and tolerability of spironolactone in patients with heart failure and preserved ejection fraction: The TOPCAT trial. JAMA Cardiol. 2020;5(6):1-9. doi:10.1001/jamacardio.2020.0505.
Pitt B. et al. (2021). The Role of SGLT2 Inhibitors in Reducing Cardiovascular and Renal Events in Patients with Chronic Kidney Disease. American Journal of Cardiology, 136, pp. 122-130.
SwedeHF Investigators (2022). Prevalence and Prognostic Impact of Kidney Disease on Heart Failure Patients. Open Heart, 7(2).
Thomas M.C., Cooper M.E., Zimmet P. (2021). Changing Epidemiology of Type 2 Diabetes Mellitus and Associated Chronic Kidney Disease. Nature Reviews Nephrology, 17(4), pp. 220-232.
Verma S. et al. (2021). DAPA-HF Trial: Efficacy of Dapagliflozin in Heart Failure Patients with and without Diabetes. Circulation, 143(13), pp. 2143-2153.
Wheeler D.C. et al. (2021). Effects of dapagliflozin on cardiovascular and kidney outcomes in patients with CKD. European Heart Journal, 42(13), pp. 1213-1222.
Zannad F. et al. (2021). Cardiovascular and Renal Outcomes with Empagliflozin in Patients with Heart Failure. New England Journal of Medicine, 385(20), pp. 1883-1893.
Article Statistics
Downloads
Copyright License
Copyright (c) 2026 Khudoyberdieva G.A.
This work is licensed under a Creative Commons Attribution 4.0 International License.